177 related articles for article (PubMed ID: 15852035)
1. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.
Savinainen JR; Kokkola T; Salo OM; Poso A; Järvinen T; Laitinen JT
Br J Pharmacol; 2005 Jul; 145(5):636-45. PubMed ID: 15852035
[TBL] [Abstract][Full Text] [Related]
2. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
Bolognini D; Cascio MG; Parolaro D; Pertwee RG
Br J Pharmacol; 2012 Apr; 165(8):2561-74. PubMed ID: 21615724
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
4. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
Thomas A; Stevenson LA; Wease KN; Price MR; Baillie G; Ross RA; Pertwee RG
Br J Pharmacol; 2005 Dec; 146(7):917-26. PubMed ID: 16205722
[TBL] [Abstract][Full Text] [Related]
5. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T
J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
9. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol.
Oka S; Wakui J; Gokoh M; Kishimoto S; Sugiura T
Eur J Pharmacol; 2006 May; 538(1-3):154-62. PubMed ID: 16647054
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
Ihenetu K; Molleman A; Parsons M; Whelan C
Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
Breivogel CS; Griffin G; Di Marzo V; Martin BR
Mol Pharmacol; 2001 Jul; 60(1):155-63. PubMed ID: 11408610
[TBL] [Abstract][Full Text] [Related]
12. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.
Zhang Y; Xie Z; Wang L; Schreiter B; Lazo JS; Gertsch J; Xie XQ
Int Immunopharmacol; 2011 Sep; 11(9):1303-10. PubMed ID: 21539938
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
14. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
[TBL] [Abstract][Full Text] [Related]
15. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.
Marini P; Cascio MG; King A; Pertwee RG; Ross RA
Br J Pharmacol; 2013 Jun; 169(4):887-99. PubMed ID: 23711022
[TBL] [Abstract][Full Text] [Related]
16. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.
Baillie GL; Horswill JG; Anavi-Goffer S; Reggio PH; Bolognini D; Abood ME; McAllister S; Strange PG; Stephens GJ; Pertwee RG; Ross RA
Mol Pharmacol; 2013 Feb; 83(2):322-38. PubMed ID: 23160940
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal inhibition of G-protein signaling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes.
Cinar R; Freund TF; Katona I; Mackie K; Szucs M
Neurochem Int; 2008 Jun; 52(8):1402-9. PubMed ID: 18407377
[TBL] [Abstract][Full Text] [Related]
18. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]